Anbio Biotechnology Class A Ordinary Shares
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNNN research report →
Price Chart
About the company
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B).
- CEO
- Michael Lau
- IPO
- 2025
- Employees
- 27
- HQ
- Frankfurt am Main, HE, DE
Get TickerSpark's AI analysis on NNNN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $202.78M
- P/E
- 23.89
- PEG
- 0.24
- P/S
- 17.22
- P/B
- 6.72
- EV/EBITDA
- 30.11
- Div Yield
- 0.00%
- Gross Margin
- 86.10%
- Op Margin
- 65.20%
- Net Margin
- 72.09%
- ROE
- 27.49%
- ROIC
- 25.46%
Latest fiscal year · YoY change
- Revenue
- $8.65M+5.6%
- Gross Profit
- $7.54M+28.2%
- Op Income
- $5.77M
- Net Income
- $6.40M+169.9%
- EPS
- $0.16+185.7%
- OCF Growth
- -423.9%
- FCF Growth
- -423.9%
- 52W High
- $44.73
- 52W Low
- $4.55
- 50D MA
- $7.34
- 200D MA
- $19.75
- Beta
- 5.26
- RSI (14)
- 28
- Avg Volume
- 146.84K
No earnings-call transcripts are available for NNNN yet.
- Free Float
- 90.4%
- Shares Outstanding
- 43.89M
- Float Shares
- 39.69M
of shares held by institutions
8 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Geode Capital Management, LLC | 26.74K | ▲ 973 |
| Bank Of America Corp | 13.42K | ▲ 13.42K |
| Bnp Paribas Arbitrage, Snc | 11.80K | ▲ 1.40K |
| Marshall Wace, Llp | 11.50K | ▲ 11.50K |
| Morgan Stanley | 7.23K | ▼ 107 |
| Ubs Group AG | 828 | ▼ 5.51K |
| Eversource Wealth Advisors, LLC | 187 | ▼ 79 |
| Advisor Group Holdings, Inc. | 77 | ▲ 77 |
| Jpmorgan Chase & Co | 53 | ▲ 53 |
| Bare Financial Services, Inc | 15 | 0 |
| Larson Financial Group LLC | 5 | ▲ 5 |
| Silver Grove Financial Group, Inc. | 4 | ▲ 4 |
Held by 2 ETFs
Biggest fund positions in NNNN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | ZHANG MICHAEL W.C | other | 0 |
| Mar 18, 26 | HSU DAVID H | other | 0 |
| Mar 18, 26 | Song Suki | other | 0 |
| Mar 18, 26 | Hartzler Nancy | other | 0 |
| Mar 18, 26 | LAU MICHAEL | other | 0 |
| Mar 18, 26 | TIAN CHRIS | other | 0 |
| Mar 18, 26 | XU CANY | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NNNN coverage
Recent articles, reports, and earnings notes.
No research on NNNN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NNNN report →Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review
defenseworld.net · Mar 9
Head-To-Head Contrast: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN)
defenseworld.net · Mar 9
Head-To-Head Analysis: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN)
defenseworld.net · Mar 7
Financial Comparison: Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX)
defenseworld.net · Mar 7
Analyzing Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX)
defenseworld.net · Mar 7
Anbio Biotechnology (NASDAQ:NNNN) vs. Oncocyte (NASDAQ:IMDX) Financial Comparison
defenseworld.net · Mar 7
Financial Analysis: Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN)
defenseworld.net · Mar 6
Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN) Critical Analysis
defenseworld.net · Mar 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.